Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease
Aging is by far the most prominent risk factor for Alzheimer's disease (AD), and both aging and AD are associated with apparent metabolic alterations. As developing effective therapeutic interventions to treat AD is clearly in urgent need, the impact of modulating whole-body and intracellular m...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-02-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S221138352100246X |
| _version_ | 1818872452742119424 |
|---|---|
| author | Steven N. Austad Scott Ballinger Thomas W. Buford Christy S. Carter Daniel L. Smith, Jr. Victor Darley-Usmar Jianhua Zhang |
| author_facet | Steven N. Austad Scott Ballinger Thomas W. Buford Christy S. Carter Daniel L. Smith, Jr. Victor Darley-Usmar Jianhua Zhang |
| author_sort | Steven N. Austad |
| collection | DOAJ |
| description | Aging is by far the most prominent risk factor for Alzheimer's disease (AD), and both aging and AD are associated with apparent metabolic alterations. As developing effective therapeutic interventions to treat AD is clearly in urgent need, the impact of modulating whole-body and intracellular metabolism in preclinical models and in human patients, on disease pathogenesis, have been explored. There is also an increasing awareness of differential risk and potential targeting strategies related to biological sex, microbiome, and circadian regulation. As a major part of intracellular metabolism, mitochondrial bioenergetics, mitochondrial quality-control mechanisms, and mitochondria-linked inflammatory responses have been considered for AD therapeutic interventions. This review summarizes and highlights these efforts. |
| first_indexed | 2024-12-19T12:39:02Z |
| format | Article |
| id | doaj.art-303bc329cf6c46dda549b830e064a1f6 |
| institution | Directory Open Access Journal |
| issn | 2211-3835 |
| language | English |
| last_indexed | 2024-12-19T12:39:02Z |
| publishDate | 2022-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj.art-303bc329cf6c46dda549b830e064a1f62022-12-21T20:21:01ZengElsevierActa Pharmaceutica Sinica B2211-38352022-02-01122511531Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's diseaseSteven N. Austad0Scott Ballinger1Thomas W. Buford2Christy S. Carter3Daniel L. Smith, Jr.4Victor Darley-Usmar5Jianhua Zhang6Department of Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USADepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USADepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USADepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USADepartment of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USADepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USADepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA; Corresponding author. Tel.: +1 205 996 5153.Aging is by far the most prominent risk factor for Alzheimer's disease (AD), and both aging and AD are associated with apparent metabolic alterations. As developing effective therapeutic interventions to treat AD is clearly in urgent need, the impact of modulating whole-body and intracellular metabolism in preclinical models and in human patients, on disease pathogenesis, have been explored. There is also an increasing awareness of differential risk and potential targeting strategies related to biological sex, microbiome, and circadian regulation. As a major part of intracellular metabolism, mitochondrial bioenergetics, mitochondrial quality-control mechanisms, and mitochondria-linked inflammatory responses have been considered for AD therapeutic interventions. This review summarizes and highlights these efforts.http://www.sciencedirect.com/science/article/pii/S221138352100246XMitochondrial DNAMitochondrial electron transport chainMitochondrial quality controlReactive speciesDAMPsHexokinase biosynthesis pathway |
| spellingShingle | Steven N. Austad Scott Ballinger Thomas W. Buford Christy S. Carter Daniel L. Smith, Jr. Victor Darley-Usmar Jianhua Zhang Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease Acta Pharmaceutica Sinica B Mitochondrial DNA Mitochondrial electron transport chain Mitochondrial quality control Reactive species DAMPs Hexokinase biosynthesis pathway |
| title | Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease |
| title_full | Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease |
| title_fullStr | Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease |
| title_full_unstemmed | Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease |
| title_short | Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease |
| title_sort | targeting whole body metabolism and mitochondrial bioenergetics in the drug development for alzheimer s disease |
| topic | Mitochondrial DNA Mitochondrial electron transport chain Mitochondrial quality control Reactive species DAMPs Hexokinase biosynthesis pathway |
| url | http://www.sciencedirect.com/science/article/pii/S221138352100246X |
| work_keys_str_mv | AT stevennaustad targetingwholebodymetabolismandmitochondrialbioenergeticsinthedrugdevelopmentforalzheimersdisease AT scottballinger targetingwholebodymetabolismandmitochondrialbioenergeticsinthedrugdevelopmentforalzheimersdisease AT thomaswbuford targetingwholebodymetabolismandmitochondrialbioenergeticsinthedrugdevelopmentforalzheimersdisease AT christyscarter targetingwholebodymetabolismandmitochondrialbioenergeticsinthedrugdevelopmentforalzheimersdisease AT daniellsmithjr targetingwholebodymetabolismandmitochondrialbioenergeticsinthedrugdevelopmentforalzheimersdisease AT victordarleyusmar targetingwholebodymetabolismandmitochondrialbioenergeticsinthedrugdevelopmentforalzheimersdisease AT jianhuazhang targetingwholebodymetabolismandmitochondrialbioenergeticsinthedrugdevelopmentforalzheimersdisease |